
Piramal Pharma: We are already in the third week of 2025 and, Piramal Pharma is trending once again. This time it’s all for unfeigned reasons. Let’s unleash the suspense and learn about the company with recent to the latest developments.
About Piramal Pharma Limited
With a distribution network spanning globally in more than 100 countries and end-to-end production capabilities across 15 locations worldwide, Piramal Pharma Limited (PPL) provides a spectrum of unique products and services. PPL consists of the India Consumer Healthcare company that sells over-the-counter goods. Through an integrated global facilities network across the medication life cycle, PPS provides innovators and generic businesses with end-to-end development and manufacturing solutions. Inhalation anesthetics, intrathecal therapies for pain and spasticity management, injectable pain, other therapies and anesthetics are all part of PCC’s extensive hospital product line.
Recent Development
Today marks for the 6.2% increase in the share of Piramal Pharma. This surge has been reported after a three-day consecutive decline. Not many were expecting this sudden spike because this spike is almost the biggest spike from past six weeks. The shares of Piramal Pharma were badly fighting with a 12% decline but now investors have gained a ray of hope with today’s surge.
Last year also, following the initiation of coverage by well-known brokerage JM Financial with a “buy” recommendation at a target price of Rs 340, Piramal Pharma shares saw an increase. This was a 30.5% increase from its previous close.
Piramal Pharma Limited’s Q3 Analysis
As per the latest data concerning the Q3 earnings, a sequential increase of solid 2.47% has been seen in the total income (₹1,958.57 Cr) of the company. The profit after tax (₹10.11 Cr) has also increased year over year by 101.39% but the operating profit stands at ₹602.56 Cr which has seen a negative change of about -3.17%.
Key Highlights of the Company
Other Key Highlights are listed down below:
The probability of the company has improved due to energy prices, lower cost of raw materials, as well as operational efficiencies.
The revenue Growth of the company is driven across ICH, CDMO, and CHG businesses.
The business has also witnessed order inflows that are strong specifically for innovative department and offerings that are differentiated.
The EBITDA of the company was also considerably better in 2024 than the year before. This was ascribed to things like reduced energy prices, cheaper raw material costs, and improved operational efficiency.
Final Verdict
In 2024, Piramal Pharma Limited showed impressive financial results, fueled by strong revenue growth in all major business divisions, increased profitability through cost optimization and notable debt reduction progress. The company’s strategic emphasis on unique services and innovation within the CDMO industry puts it in a favorable position for steady growth.
For more such insights, check out the Angelone application, wherein you can create your Demat account with a single tap and start your investor journey instantly.
Disclaimer: Demat Dive is not giving any buying advice on any stock. Consult a SEBI-registered advisor before investing anywhere.